Skip to main content
Quest Diagnostics

Musculoskeletal and Body Composition Responses to High-Dose Testosterone with Finasteride after Chronic Incomplete Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Musculoskeletal and Body Composition Responses to High-Dose Testosterone with Finasteride after Chronic Incomplete Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Authors: Otzel DM, Nichols L, Conover CF, Marangi SA, Kura JR, Iannaccone DK, Clark DJ, Gregory CM, Sonntag CF, Wokhlu A, Ghayee HK, McPhaul MJ, Levy CE, Plumlee CA, Sammel RB, White KT, Yarrow JF

Citation: Front Neurol. 2024 Dec 11;15:1479264. doi: 10.3389/fneur.2024.1479264.

Specialties: Cardiology, Endocrinology, Neurology

Related content

Publication
Pharmacologic or Genetic Interference With Atrogene Signaling Protects Against Glucocorticoid-Induced Musculoskeletal and Cardiac Disease

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.